- Trial phase
- unknown (no registered ClinicalTrials.gov record found; appears to be an early, minimally disclosed pipeline program)
- Time to market
- unknown, no clinical trial or development phase disclosed in any retrievable source
- Why 2/10
- No hard, dated catalyst (PDUFA, pivotal readout, or trial registration) for ALN-6222 exists in any source retrieved this session, and it appears to be an early-stage program inside a large multi-program company, so a big share-price move driven specifically by this drug in ~12 months is unlikely.
ALN-6222 is real (it appears in Alnylam's Q2 2026 pipeline listing in the 8-K filed 2026-07-30) but is essentially undisclosed, no target, indication, or clinical trial could be found. Investors should not trade ALNY on this code; wait for Alnylam corporate/R&D pipeline updates (typically year-end R&D events) to disclose the program's target and phase, and treat any news as early-stage speculation. Company-level drivers (TTR franchise guidance, zilebesiran/mivelsiran readouts) are what actually move ALNY.
Price Chart
Executive Summary
ALN-6222 is a development-code RNAi program at Alnylam Pharmaceuticals (Nasdaq: ALNY, ~$38B market cap per the Q2 2026 earnings analysis). This is a genuine but essentially opaque early-stage program, a tiny sliver of Alnylam's value, which is driven by its approved TTR franchise (Amvuttra) and late-stage candidates. The drug-specific rating is neutral because there is not enough public information to form a directional view; company-level sentiment is currently bearish after a Q2 earnings miss and full-year TTR guidance cut.
How It Works
Alnylam specializes in RNA-interference (RNAi) medicines, small molecules that silence disease-causing genes. ALN-6222 follows the company's "ALN-" naming convention for an investigational RNAi candidate, but its gene target, disease indication, and mechanism have not been publicly disclosed in any source retrievable this session, so nothing can be verified about how it works.
Trial Status
None found. ALN-6222 is listed among Alnylam's pipeline programs in the Q2 2026 earnings release (8-K filed 2026-07-30), alongside marketed drugs (Amvuttra, Onpattro, Givlaari, Oxlumo), late-stage candidates (nucresiran, zilebesiran, mivelsiran) and other early codes (ALN-6400, ALN-2232, ALN-5288, ALN-HTT02).
The Two-Sided Case
Upcoming Catalysts
- None identified for ALN-6222 specifically in any retrieved source.
- Watch for Alnylam corporate pipeline/R&D updates (the company typically details early programs at its year-end R&D event) where ALN-6222's target, indication, and phase may first be disclosed.
- Company-level catalysts that actually move ALNY: Q3 2026 earnings (guidance trajectory after the cut), and readouts/progress on late-stage programs zilebesiran, nucresiran, and mivelsiran.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ALNYLAM PHARMACEUTICALS, INC. 8-K ALNY ·Originating report